Clinical Trial

Tight Versus Liberal Blood Glucose Control in Adult Critically Ill Patients

Study acronym: TGC-fast
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Critically ill patients usually develop hyperglycemia, which is associated with an increased risk of morbidity and mortality. Controversy exists on whether targeting normal blood glucose concentrations with insulin therapy, referred to as tight blood glucose control (TGC) improves outcome of these patients, as compared to tolerating hyperglycemia. It remains unknown whether TGC, when applied with optimal tools to avoid hypoglycemia, is beneficial in a context of withholding early parenteral nutrition. The TGC-fast study hypothesizes that TGC is beneficial in adult critically ill patients not receiving early parenteral nutrition, as compared to tolerating hyperglycemia.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2018-09-07; most recent amendment 2023-06-02.
Status change: Recruiting → Active, Not Recruiting 2023-06-02
Status change: Not Yet Recruiting → Recruiting 2018-09-28
Trial Details
NCT Number NCT03665207
Lead Sponsor KU Leuven
Collaborators: Universitaire Ziekenhuizen KU Leuven, Research Foundation Flanders
Conditions Critical Illness, Hyperglycemia
Enrollment 9,230 participants
Start Date 2018-09-18
Primary Completion 2022-11-30 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2023-06-05